(Press-News.org) A new study from Karolinska Institutet, published in the scientific journal The BMJ, shows how a simple blood analysis can predict the risk of developing severe liver disease. The method may already start to be applied in primary care to enable the earlier detection of cirrhosis and cancer of the liver.
“These are diseases that are growing increasingly common and that have a poor prognosis if detected late,” says Rickard Strandberg, affiliated researcher at Karolinska Institutet’s Department of Medicine in Huddinge, who has developed the test with his departmental colleague Hannes Hagström. “Our method can predict the risk of severe liver disease within 10 years and is based on three simple routine blood tests.”
For the study, the researchers at Karolinska Institutet in Sweden and their colleagues in Finland evaluated how well the method can estimate the risk of severe liver disease. The model, which is called CORE, was produced with advanced statistical methods and is based on five factors: age, sex and levels of three common liver enzymes (AST, ALT and GGT), which are commonly measured during regular health checks.
A web-based calculator
Their aim has been to produce a tool that is easy to use in primary care, where most patients first seek medical attention. A web-based calculator is already available for doctors and nurses at www.core-model.com.
“This is an important step towards being able to offer early screening for liver disease in primary care,” says principal investigator Hannes Hagström, adjunct professor at Karolinska Institutet’s Department of Medicine in Huddinge, and senior consultant at Karolinska University Hospital. “Drug treatment is now available, soon hopefully also in Sweden, for treating people at a high risk of developing liver diseases such as cirrhosis or liver cancer.”
The study is based on data from over 480,000 people in Stockholm who underwent health checks between 1985 and 1996. On following the participants for up to 30 years, the researchers could see that some 1.5 per cent developed severe liver disease, such as liver cirrhosis and liver cancer, or required a liver transplant.
Highly accurate risk prediction
The CORE model proved highly accurate and was able to differentiate between people who either did or did not develop the disease in 88 per cent of cases, which is an improvement on the currently recommended FIB-4 method.
“Primary care hasn’t had the tools to detect the risk of severe liver disease in time,” says Professor Hagström. “FIB-4 is not suited for the general population and is less effective at predicting the future risk of severe liver disease.”
The model was also tested on two other population groups in Finland and the UK, where it again demonstrated a high accuracy in predicting this risk. The researchers make the point, however, that it needs to be further tested on groups at especially high risk, such as people with type 2 diabetes or obesity. They also recognise a need to integrate the model into medical records systems to facilitate its clinical use.
The study was a collaboration between Karolinska Institutet, Helsinki University Hospital, Helsinki University and the Finnish Institute for Health and Welfare. It was financed by the Swedish Research Council, Region Stockholm (CIMED) and the Swedish Cancer Society. Hannes Hagström is engaged in several collaborations with the pharmaceutical industry regarding liver disease prognosis, but none that is relevant to the current study.
Publication: “Use of new CORE risk score to predict 10 year risk of liver cirrhosis in general population: population based cohort study”, Rickard Strandberg, Fredrik Åberg, Juho V Asteljoki, Panu K Luukkonen, Veikko Salomaa, Antti Jula, Annamari Lundqvist, Satu Männistö, Markus Perola, Mats Talbäck, Niklas Hammar, Hannes Hagström, The BMJ, online 29 September 2025, doi: 10.1136/bmj-2024-083182.
END
Simple test can predict risk of severe liver disease
2025-09-29
ELSE PRESS RELEASES FROM THIS DATE:
RSV vaccines safe and effective, Cochrane review finds
2025-09-29
The review demonstrates that vaccines for respiratory syncytial virus (RSV) are both safe and effective in protecting groups who are most at risk for serious illness, including older adults and infants.
RSV is a common virus that causes coughs and colds but can also lead to life-threatening lung infections like pneumonia. Children under the age of two months are at the highest risk of severe RSV infection and death, with older adults also vulnerable to severe disease.
An international group of researchers analysed 14 ...
Unplanned, premature, out-of-hospital births pose challenges for emergency team
2025-09-28
Vienna, Austria: The first detailed analysis of unplanned births that occurred outside the hospital setting in Austria has shown that, although such deliveries are rare, they pose challenges for emergency teams that attend, especially if babies are born prematurely [1].
In a study presented at the European Emergency Medicine Congress today (Monday), the researchers found that between 2017 and 2024 there were 173 unplanned, out-of-hospital births in the Styria region of Austria, of which 16 (9%) were premature (less than 37 weeks’ gestation). The most premature ...
Hypnosis can make ventilation masks more acceptable to patients with breathing problems
2025-09-28
Vienna, Austria: Hypnosis can significantly improve patients’ tolerance of masks to help them breathe when they are suffering from acute respiratory failure, according to a pilot study presented at the European Emergency Medicine Congress today (Monday) [1].
People who come to hospital with breathing problems are often given non-invasive ventilation (NIV) via a mask and tubes connected to a machine in order increase the amount of oxygen in their blood and lower carbon dioxide levels. However, some ...
‘Staggering’ costs of e-scooter injuries are quantified for the first time for hospitals in Ireland
2025-09-28
Vienna, Austria: Injuries occurring to people who ride e-scooters cost Irish hospitals an average of €1,726 per patient, and researchers have calculated the total overall cost to one hospital in a single year was €128,650.
Dr Thomas Suttie, a senior house officer in emergency medicine at Connolly Hospital Blanchardstown, Abbotstown, Dublin, Ireland, told the European Emergency Medicine Congress today (Monday): “In 2021 we published the number of patients who came to the emergency department of ...
People may age faster if their dad smoked during puberty
2025-09-28
People whose fathers smoked during puberty seem to age faster than expected, according to research presented at the European Respiratory Society (ERS) Congress in Amsterdam, the Netherlands [1].
The researchers found signs of faster biological ageing, compared to chronological age, in people whose fathers began smoking at age 15 or younger. They say smoking during puberty may create damage in boys’ developing sperm cells that can be passed on to their children.
The researchers call for stronger efforts to prevent tobacco use in teenagers, not only ...
Higher levels of air pollution linked to worsening of sleep apnea
2025-09-28
People who have obstructive sleep apnoea (OSA) may suffer worse symptoms if they live in areas with higher levels of air pollution, according to a multi-national study presented at the European Respiratory Society (ERS) Congress in Amsterdam, the Netherlands [1].
Patients with OSA often snore loudly, their breathing starts and stops during the night, and they may wake up several times. Not only does this cause excessive sleepiness, but it can also increase the risk of high blood pressure, stroke, heart disease and type 2 diabetes. OSA is very common, ...
ASTRO: New therapy delays progression of recurrent prostate cancer
2025-09-28
Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease worsening compared with those who received SBRT alone, according to new clinical trial results from UCLA Health Jonsson Comprehensive Cancer Center researchers.
Findings from the trial, presented today at the 2025 American Society for Radiation Oncology Annual Meeting in San Francisco, showed that men who received the radioligand drug ...
Low-dose radiation therapy offers substantial relief to people with painful knee osteoarthritis
2025-09-28
SAN FRANCISCO, September 28, 2025 — A single course of low-dose radiation therapy may provide a safe and effective alternative treatment option for people with painful knee osteoarthritis according to a new randomized, placebo-controlled clinical trial.
The study showed patients with mild to moderate knee osteoarthritis reported significant reductions in pain and improved physical function in the four months after receiving the low dose of radiation, which was just a small fraction of what’s used to treat cancer. Because the study included a control group with simulated treatment, the researchers could distinguish ...
Radiopharmaceutical added to stereotactic radiation delays prostate cancer progression in patients with limited metastatic disease
2025-09-28
SAN FRANCISCO, September 28, 2025 — A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutical drug before targeted radiation, compared with radiation alone.
The phase II LUNAR trial is the first randomized study to show that a treatment established for later-stage prostate cancer can delay progression and defer hormone therapy when added to high-precision radiation ...
First-of-its-kind genomic test predicts benefit from hormone therapy added to radiation for recurrent prostate cancer
2025-09-28
SAN FRANCISCO, September 28, 2025 — A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery — the first predictive biomarker in this setting.
In the first prospective, randomized trial to validate a predictive gene expression test for hormone therapy in prostate cancer, patients with a prostate tumor subtype known as luminal B had much lower risks of recurrence and metastasis when radiation was complemented by apalutamide, a type of hormone therapy. Patients without this tumor subtype, however, saw no improvement. ...